TO: Vaccines for Children (VFC) Providers
FROM: John Talarico, D.O., M.P.H., Chief
       Center for Infectious Diseases
       Division of Communicable Disease Control, Immunization Branch

Subject: Expanded Indications for MCV4 include High-Risk Children

Summary

In addition to a routine dose at 11-12 years old and a booster dose for adolescents at age 16 years, ACIP now also recommends meningococcal conjugate vaccine (MCV4) for high-risk children as young as 9 months of age.

New: MCV4 for High-Risk Children as Young as Age 9 months

In October 2011, ACIP provided expanded recommendations for the use of quadrivalent meningococcal conjugate vaccine (MCV4) in children as young as 9 months of age who are at increased risk of developing meningococcal disease.

Children 9 months-23 months of age with the following risks should receive a primary series of 2 doses of MCV4, 3 months apart:

- Those with persistent complement component deficiencies
- Traveling to or residing in countries where meningococcal disease is hyperendemic or epidemic
- In a defined risk group during a community or institutional meningococcal outbreak

Children 2-10 years of age with the following risks should receive a primary series of 2 doses of MCV4, 2 months apart:

- Functional or anatomic asplenia
- Persistent complement component deficiencies and no prior doses of MCV4
- At increased risk of meningococcal disease and infected with HIV
Expanded Indications for MCV4 include High-Risk Children

November 23, 2011
Page 2 of 3

Children 2-10 years of age not previously immunized with MCV4 and with the following risks **should receive 1 dose of MCV4:**

- Traveling to or reside in countries where meningococcal disease is hyperendemic or epidemic;
- In a defined risk group during a community or institutional meningococcal outbreak.

**Reminder: ACIP recommends a booster dose of MCV4 for Older Adolescents**

<table>
<thead>
<tr>
<th>Age in years at first dose of MCV4</th>
<th>Age in years for booster dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 or 12</td>
<td>16</td>
</tr>
<tr>
<td>13 through 15</td>
<td>16 through 18</td>
</tr>
<tr>
<td>≥16</td>
<td>No booster dose needed.</td>
</tr>
</tbody>
</table>

**Current FDA License Age Indications for MCV4**
- Menactra® (sanofi pasteur) -- 9 months through 55 years of age.
- Menveo® (Novartis Vaccines and Diagnostics, Inc.) -- 2 through 55 years of age.

**Vaccine Information Statement (VIS)**
The updated MCV4 vaccine information statement, with new information on contraindications, precautions and adverse events, can be downloaded at [www.EZIZ.org](http://www.EZIZ.org).

**ACIP Recommendations on MCV4**
Providers are encouraged to review the details of ACIP recommendations for MCV4:

- Use in children as young as 9 months - October 2011 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm)
- Use in high-risk children age 2 through 10 years; updated booster guidance - August 2011 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6030a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6030a3.htm)
- Adolescent booster dose - January 2011 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm)
- Revaccination of persons at prolonged increased risk for meningococcal disease - September 2009 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s_cid=mm5837a4_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s_cid=mm5837a4_e)

**Questions?**
If you have any questions, please call your VFC Field Representative or the VFC Program at 877-243-8832 (877-2GET-VFC) or visit [www.EZIZ.org](http://www.EZIZ.org).
Expanded Indications for MCV4 include High-Risk Children
November 23, 2011
Page 3 of 3

cc: CDPH Immunization Branch Field Representatives
Local Health Officers
Local Health Department Immunization Coordinators
Local Health Department CHDP Program Directors
Jane Ogle, Acting Chief, Medi-Cal Managed Care Division, DHCS
Shabbir Ahmad, D.V.M., M.S., Ph.D., Acting Chief, Maternal, Child and Adolescent Health Program, CDPH
Laurie Weaver, Chief, Office of Family Planning, CDPH
Shelley Rouillard, Deputy Director, Benefits and Quality Monitoring Division, MRMIB
Emmee Nguyen, Benefits and Quality Monitoring, MRMIB
Jill Young, Benefits and Quality Monitoring, MRMIB
Sherie Smalley, M.D., Chief, Medi-Cal Policy and Benefits Branch, Medi-Cal Benefits, Waiver Analysis and Rates Division, DHCS
Steve Shih, M.D. Medical Policy Section, Medi-Cal Benefits, Waiver Analysis and Rates Division, DHCS
Alan Morita, Pharm.D., Medi-Cal Pharmacy Policy Branch, DHCS
Robert Dimand, M.D., Chief, Children Medical Services Branch, DHCS
Jill Abramson, M.D., M.P.H., Children Medical Services Branch, DHCS